A	O
Recombinant	B:C0017387
Human	O
Anti-Platelet	O
scFv	I:C0370058
Antibody	I:C0370058
Produced	O
in	O
Pichia	O
pastoris	I:C0997362
for	O
Atheroma	O
Targeting	O
.	O

A	O
Recombinant	O
Human	B:C0086418
Anti-Platelet	O
scFv	I:C0370058
Antibody	I:C0370058
Produced	O
in	O
Pichia	O
pastoris	I:C0997362
for	O
Atheroma	O
Targeting	O
.	O

A	O
Recombinant	O
Human	O
Anti-Platelet	B:C0370058
scFv	I:C0370058
Antibody	I:C0370058
Produced	O
in	O
Pichia	O
pastoris	I:C0997362
for	O
Atheroma	O
Targeting	O
.	O

A	O
Recombinant	O
Human	O
Anti-Platelet	O
scFv	I:C0370058
Antibody	I:C0370058
Produced	O
in	O
Pichia	B:C0997362
pastoris	I:C0997362
for	O
Atheroma	O
Targeting	O
.	O

A	O
Recombinant	O
Human	O
Anti-Platelet	O
scFv	I:C0370058
Antibody	I:C0370058
Produced	O
in	O
Pichia	O
pastoris	I:C0997362
for	O
Atheroma	B:C0264956
Targeting	O
.	O

Cells	B:C0007634
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	B:C0020962
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	B:C0242656
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	B:C2936350
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	B:C0332461
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	B:C1444783
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	B:C3203359
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	B:C1963943
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	B:C0010054
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	B:C0007820
disease	I:C0007820
and	O
peripheral	O
arterial	I:C0085096
disease	I:C0085096
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	I:C0020962
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	I:C2936350
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	I:C0010054
disease	I:C0010054
,	O
cerebrovascular	O
disease	I:C0007820
and	O
peripheral	B:C0085096
arterial	I:C0085096
disease	I:C0085096
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	B:C0525050
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	B:C1171362
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	B:C0220825
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	B:C1883036
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	B:C1883036
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	B:C0086418
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	B:C0016011
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	B:C0016011
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	B:C0264956
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	B:C0221198
for	O
the	O
presence	O
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	B:C0150312
of	O
platelets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single	O
-	I:C1883036
chain	I:C1883036
variable	I:C1883036
fragment	I:C1883036
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αII	O
b	I:C0016011
β3	I:C0016011
antibody	I:C0016011
(	O
human	O
anti-αII	I:C0016011
b	I:C0016011
β	I:C0016011
3	I:C0016011
antibody	I:C0016011
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	B:C0005821
.	O

Indeed	O
,	O
platelets	B:C0005821
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	B:C2936350
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	B:C0021368
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	B:C0005821
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	B:C0023516
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	B:C0087086
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	B:C0005516
of	O
atherosclerotic	O
progression	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	I:C2936350
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	B:C0242656
.	O

The	O
DNA	B:C0162326
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	B:C1883036
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	B:C3494191
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	B:C0005821
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	B:C1512796
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	B:C0684063
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	B:C1514152
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	B:C1514152
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	B:C0162326
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	B:C0010654
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	I:C0022885
.	O

The	O
DNA	O
sequence	I:C0162326
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	I:C1883036
scFv	I:C1883036
previously	O
obtained	O
from	O
a	O
phage	O
-	I:C3494191
display	I:C3494191
selection	I:C3494191
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	I:C0162326
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	B:C0022885
experiments	I:C0022885
.	O

The	O
recombinant	B:C0034861
protein	I:C0034861
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	I:C0997362
(	O
30	O
mg	O
/L	O
culture	O
)	O
.	O

The	O
recombinant	O
protein	I:C0034861
was	O
expressed	B:C1171362
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	I:C0997362
(	O
30	O
mg	O
/L	O
culture	O
)	O
.	O

The	O
recombinant	O
protein	I:C0034861
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	B:C0997362
pastoris	I:C0997362
(	O
30	O
mg	O
/L	O
culture	O
)	O
.	O

The	O
recombinant	O
protein	I:C0034861
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	I:C0997362
(	O
30	O
mg	O
/L	O
culture	B:C0010454
)	O
.	O

The	O
advantage	O
of	O
P.	B:C0997362
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	B:C1171362
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	B:C0036536
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	B:C0034861
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	B:C1550101
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	B:C1883036
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	B:C0010834
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	B:C0004611
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	I:C0997362
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	I:C0034861
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	B:C0003255
)	O
.	O

The	O
improved	B:C0184511
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	B:C0574031
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	B:C0205145
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	B:C0011923
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	B:C2936350
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	B:C0332167
risk	I:C0332167
of	I:C0332167
instability	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	I:C0574031
scFv	I:C0574031
fragments	I:C0574031
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	I:C2936350
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	I:C0332167
of	I:C0332167
instability	B:C1444783
.	O

